Search for a trial

Investigation of the AcrySof® IQ PanOptix* Presbyopia Correcting IOL Model TFNT00

The objective of this investigation is to describe visual outcomes and assess the safety at 12 months (330 - 420 days) post bilateral implantation of the AcrySof® IQ PanOptix* Presbyopia correcting IOL Model TFNT00.

protocol C-10-017: 'Lens Wearing Experience and Biocompatibility of a Marketed MPDS in Silicone Hydrogel and Soft Contact Lens Wearers'

The primary statistical objective of this study is to describe mean differences in corneal staining (type and area), for OPTI-FREE EverMoist Multi-Purpose Disinfecting Solution compared to baseline.

A 56-week phase IIIb/IV, open-label, one-arm extension study to assess the efficacy and safety of brolucizumab 6mg in a Treat-to-Control regimen with maximum treatment intervals up to 20 weeks for the treatment of patients with neovascular Age-related Macular Degeneration who have completed the CRTH258A2303 (TALON) study

The purpose of this study is to evaluate the efficacy and safety of brolucizumab used in a Treat- to-Control (TtC) regimen with maximum treatment intervals up to 20 weeks for the treatment of patients with neovascular age-related macular…

Post-Market Clinical Investigation of the Clareon® IOL

Primary Objective:The primary objective of this study is to demonstrate the long-term (3 years) favorable visual acuity and adverse event outcomes for the Clareon IOL compared to historical SPE rates as reported in EN ISO 11979-7:2014.Secondary…